EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase II)VergleichsstudieOpen Access · CC BY 4.0

Comparison of Two High-Dose Versus Two Standard-Dose Influenza Vaccines in Adult Allogeneic Hematopoietic Cell Transplant Recipients

Lora D Thomas iD, Einas Batarseh, Lubna Hamdan, Zaid Haddadin, Daniel Dulek, Spyros Kalams, Laura S Stewart, Anna L Stahl, Herdi Rahman, Justin Z Amarin, Haya Hayek, Michael Ison und 5 weitere

Clinical Infectious Diseases · 15.12.2023 · 77 (12) · 1723-1732

DOI: 10.1093/cid/ciad458 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Infectious Diseases, online erschienen am 16.08.2023. Verfasst von Lora D Thomas und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Virginia Commonwealth University Medical Center, Richmond, Virginia, USA. Hauptthemen laut MEDLINE: Influenza Vaccines, Hematopoietic Stem Cell Transplantation, Influenza, Human, Antibodies, Viral. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH, NCATS NIH HHS, NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Adult hematopoietic cell transplant (HCT) recipients are at high risk for influenza-related morbidity and mortality and have suboptimal influenza vaccine immune responses compared to healthy adults, particularly within 2 years of transplant.

Methods

This phase II, double-blind, multicenter randomized controlled trial compared 2 doses of high-dose trivalent (HD-TIV) to 2 doses of standard-dose quadrivalent (SD-QIV) influenza vaccine administered 1 month apart in adults 3–23 months post-allogeneic HCT. Hemagglutinin antibody inhibition (HAI) titers were measured at baseline, 4 weeks following each vaccine dose, and approximately 7 months post-second vaccination. Injection-site and systemic reactions were assessed for 7 days post-vaccination. The primary immunogenicity comparison was geometric mean HAI titer (GMT) at visit 3 (4 weeks after the second dose); we used linear mixed models to estimate adjusted GMT ratios (aGMRs) comparing HD-TIV/SD-QIV for each antigen.

Results

We randomized 124 adults; 64 received SD-QIV and 60 received HD-TIV. Following the second vaccination, HD-TIV was associated with higher GMTs compared to SD-QIV for A/H3N2 (aGMR = 2.09; 95% confidence interval [CI]: [1.19, 3.68]) and B/Victoria (aGMR = 1.61; 95% CI: [1.00, 2.58]). The increase was not statistically significant for A/H1N1 (aGMR = 1.16; 95% CI: [0.67, 2.02]). There was a trend to more injection-site reactions for HD-TIV after the second vaccination compared to SD-QIV (50% vs 33%; adjusted odds ratio [aOR] = 4.53; 95% CI: [0.71, 28.9]), whereas systemic reactions were similar between groups with both injections.

Conclusions

Adult allogeneic HCT recipients who received 2 doses of HD-TIV produced higher HAI antibody responses for A/H3N2 and B/Victoria compared with 2 doses of SD-QIV, with comparable injection-site or systemic reactions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Influenza VaccinesHematopoietic Stem Cell TransplantationInfluenza, HumanAntibodies, ViralHumansMaleMiddle AgedFemaleAdultDouble-Blind MethodYoung AdultAgedTransplant RecipientsInfluenza A Virus, H3N2 SubtypeHemagglutination Inhibition TestsInfluenza A Virus, H1N1 SubtypeTransplantation, HomologousVaccinationInfluenza B virusImmunogenicity, Vaccine

Stichwörter der Autor:innen

hematopoietic cell transplantinfluenza vaccine

Substanzen

Influenza VaccinesAntibodies, Viral

Autor:innen und Institutionen

  • Department of Medicine, Virginia Commonwealth University Medical Center, Richmond, Virginia, USA.
  • Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • 3Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Respiratory Disease Branch, Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, USA.
  • Department of Medicine, University Hospital, University of Alabama at Birmingham, Birmingham, Alabama, USA.
  • Department of Medicine, Fred Hutchinson Cancer Center, Seattle, Washington, USA.

ORCID-Profile: Lora D Thomas

Förderung

  • NIH
  • NCATS NIH HHS
  • NIAID NIH HHS

Zitieren

APA

Thomas, L. D., Batarseh, E., Hamdan, L., Haddadin, Z., Dulek, D., Kalams, S., Stewart, L. S., Stahl, A. L., Rahman, H., Amarin, J. Z., Hayek, H., Ison, M., Overton, E. T., Pergam, S. A., Spieker, A. J., Halasa, N. B., & Adult HCT Flu Study (2023). Comparison of Two High-Dose Versus Two Standard-Dose Influenza Vaccines in Adult Allogeneic Hematopoietic Cell Transplant Recipients. Clinical Infectious Diseases, 77(12), 1723-1732. https://doi.org/10.1093/cid/ciad458

Vancouver

Thomas LD, Batarseh E, Hamdan L, Haddadin Z, Dulek D, Kalams S, et al. Comparison of Two High-Dose Versus Two Standard-Dose Influenza Vaccines in Adult Allogeneic Hematopoietic Cell Transplant Recipients. Clinical Infectious Diseases. 2023;77(12):1723-1732. doi:10.1093/cid/ciad458

BibTeX
@article{Thomas2023,
  author = {Thomas, Lora D and Batarseh, Einas and Hamdan, Lubna and Haddadin, Zaid and Dulek, Daniel and Kalams, Spyros and Stewart, Laura S and Stahl, Anna L and Rahman, Herdi and Amarin, Justin Z and Hayek, Haya and Ison, Michael and Overton, Edgar T and Pergam, Steven A and Spieker, Andrew J and Halasa, Natasha B and Adult HCT Flu Study, Adult HCT Flu Study},
  title = {Comparison of Two High-Dose Versus Two Standard-Dose Influenza Vaccines in Adult Allogeneic Hematopoietic Cell Transplant Recipients},
  journal = {Clinical Infectious Diseases},
  year = {2023},
  volume = {77},
  number = {12},
  pages = {1723--1732},
  doi = {10.1093/cid/ciad458}
}
Kostenlos starten →